[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].

MMW Fortschr Med

Praxis für Dermatologie und Allergologie Augsburg.

Published: December 2008

Download full-text PDF

Source

Publication Analysis

Top Keywords

[egfr epidermal
4
epidermal growth
4
growth factor
4
factor receptor
4
receptor inhibitor-associated
4
inhibitor-associated skin
4
skin disorders
4
disorders tumor
4
tumor therapy]
4
[egfr
1

Similar Publications

Proteomics analysis reveals age-related proteins in the urine of chronic kidney disease patients.

Front Med (Lausanne)

January 2025

Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu, China.

Chronic kidney disease (CKD) is closely linked to the aging process, making the identification of protein biomarkers that reflect aging in specific organs and tissues crucial for a deeper understanding of this phenomenon. This study aimed to identify potential aging-related proteins present in the urine of CKD patients. Utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomic analysis, we identified a total of 1,712 proteins in the urine samples from both healthy controls and CKD patients in our discovery cohort.

View Article and Find Full Text PDF

Objective: This meta-analysis aims to evaluate the diagnostic accuracy of magnetic resonance imaging (MRI) based radiomic features for predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastases.

Methods: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, Scopus, Wanfang, and China National Knowledge Infrastructure (CNKI) for studies published up to April 30, 2024. We included those studies that utilized MRI-based radiomic features to detect EGFR mutations in NSCLC patients with brain metastases.

View Article and Find Full Text PDF

Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis.

Front Cell Dev Biol

January 2025

Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Background: The high morbidity and mortality rates of colorectal cancer (CRC) have been a public health concern globally, and the search for additional therapeutic options is imminent. Hyodeoxycholic acid (HDCA) has been receiving attention in recent years and has demonstrated potent efficacy in several diseases. Nonetheless, the antitumor effects and molecular pathways of HDCA in CRC remain largely unexplored.

View Article and Find Full Text PDF

Unleashing the Power of Covalent Drugs for Protein Degradation.

Med Res Rev

January 2025

Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Targeted protein degradation (TPD) has emerged as a significant therapeutic approach for a variety of diseases, including cancer. Advances in TPD techniques, such as molecular glue (MG) and lysosome-dependent strategies, have shown substantial progress since the inception of the first PROTAC in 2001. The PROTAC methodology represents the forefront of TPD technology, with ongoing evaluation in more than 20 clinical trials for the treatment of diverse medical conditions.

View Article and Find Full Text PDF

Porcine reproductive and respiratory syndrome virus (PRRSV) presents significant economic challenges to the global pork industry due to its ability to mutate rapidly. The current commercial vaccines have limited effectiveness, and there are strict restrictions on the use of antiviral chemical drugs. Therefore, it is urgent to identify new strategies for preventing and controlling PRRSV infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!